Literature DB >> 26590985

TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy.

Kasper Drimer Berg1, Davide Soldini2, Maria Jung3, Dimo Dietrich3, Carsten Stephan4, Klaus Jung5, Manfred Dietel6, Ben Vainer7, Glen Kristiansen8.   

Abstract

BACKGROUND: Transient receptor potential cation channel, subfamily M, member 4 (TRPM4) messenger RNA (mRNA) has been shown to be upregulated in prostate cancer (PCa) and might be a new promising tissue biomarker. We evaluated TRPM4 protein expression and correlated the expression level with biochemical recurrence (BR) following radical prostatectomy (RP).
MATERIAL AND METHODS: The study included 614 patients who had undergone RP. TRPM4 immunohistochemical staining was performed on samples of benign tissue, tissue containing PIN glands and PCa tissue using a commercially available polyclonal antibody. Staining intensity was recorded by two independent observers using a four-tired semi-quantitative grading system (0, 1+, 2+, 3+) converted into H-scores. Interobserver agreement was calculated by linear weighted kappa statistics. The association between staining intensity and BR was analysed using the Kaplan-Meier estimator and uni- and multiple Cox proportional hazard regression models.
RESULTS: Significantly higher staining intensity was found in PCa glands compared to benign glands (p < 0.001). The concordance rate in TRPM4 staining intensities for benign, PIN and PCa tissue ranged from 86.0 to 91.5 %, corresponding to linear weighted kappa values of 0.566-0.789. After adjusting for patient and tumour characteristics, patients with a higher staining intensity in PCa glands compared to matched benign glands and an H-score equal to or above the median had an increased risk of BR (HR 1.79-2.62; p = 0.01-0.03 for the two observers) when compared to patients with a lower staining intensity.
CONCLUSIONS: TRPM4 protein expression is widely expressed in benign and cancerous prostate tissue, with highest staining intensities found in PCa. Overexpression of TRPM4 in PCa (combination of high staining intensity and a high H-score) is associated with increased risk of BR after RP.

Entities:  

Keywords:  Immunohistochemistry; Interobserver variation; Prostate cancer; Radical prostatectomy; TRPM4; Tissue biomarker

Mesh:

Substances:

Year:  2015        PMID: 26590985     DOI: 10.1007/s00428-015-1880-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  37 in total

1.  Critical role for transient receptor potential channel TRPM4 in myogenic constriction of cerebral arteries.

Authors:  Scott Earley; Brian J Waldron; Joseph E Brayden
Journal:  Circ Res       Date:  2004-10-07       Impact factor: 17.367

2.  The TRPM4 non-selective cation channel contributes to the mammalian atrial action potential.

Authors:  Christophe Simard; Thomas Hof; Zakia Keddache; Pierre Launay; Romain Guinamard
Journal:  J Mol Cell Cardiol       Date:  2013-02-13       Impact factor: 5.000

3.  TRP channels in prostate cancer: the good, the bad and the ugly?

Authors:  Dimitra Gkika; Natalia Prevarskaya
Journal:  Asian J Androl       Date:  2011-05-30       Impact factor: 3.285

4.  TRPM4 is a Ca2+-activated nonselective cation channel mediating cell membrane depolarization.

Authors:  Pierre Launay; Andrea Fleig; Anne Laure Perraud; Andrew M Scharenberg; Reinhold Penner; Jean Pierre Kinet
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

5.  Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells.

Authors:  K Vanoverberghe; F Vanden Abeele; P Mariot; G Lepage; M Roudbaraki; J L Bonnal; B Mauroy; Y Shuba; R Skryma; N Prevarskaya
Journal:  Cell Death Differ       Date:  2004-03       Impact factor: 15.828

6.  Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.

Authors:  Jennifer R Rider; Fredrik Sandin; Ove Andrén; Peter Wiklund; Jonas Hugosson; Pär Stattin
Journal:  Eur Urol       Date:  2012-08-10       Impact factor: 20.096

7.  Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8.

Authors:  Andrea Kiessling; Susanne Füssel; Marc Schmitz; Stefan Stevanovic; Axel Meye; Bernd Weigle; Ulrich Klenk; Manfred P Wirth; Ernst P Rieber
Journal:  Prostate       Date:  2003-09-01       Impact factor: 4.104

8.  Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse.

Authors:  Susan M Henshall; Daniel E H Afar; Jordan Hiller; Lisa G Horvath; David I Quinn; Krishan K Rasiah; Kurt Gish; Dorian Willhite; James G Kench; Margaret Gardiner-Garden; Phillip D Stricker; Howard I Scher; John J Grygiel; David B Agus; David H Mack; Robert L Sutherland
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

9.  Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression.

Authors:  Thomas Fixemer; Ulrich Wissenbach; Veit Flockerzi; Helmut Bonkhoff
Journal:  Oncogene       Date:  2003-10-30       Impact factor: 9.867

10.  GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.

Authors:  G Kristiansen; F R Fritzsche; K Wassermann; C Jäger; A Tölls; M Lein; C Stephan; K Jung; C Pilarsky; M Dietel; H Moch
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

View more
  15 in total

Review 1.  New Progress of Epigenetic Biomarkers in Urological Cancer.

Authors:  Peng Wu; Ziyi Cao; Song Wu
Journal:  Dis Markers       Date:  2016-08-09       Impact factor: 3.434

2.  Neem leaf glycoprotein prevents post-surgical sarcoma recurrence in Swiss mice by differentially regulating cytotoxic T and myeloid-derived suppressor cells.

Authors:  Madhurima Sarkar; Sarbari Ghosh; Avishek Bhuniya; Tithi Ghosh; Ipsita Guha; Subhasis Barik; Jaydip Biswas; Anamika Bose; Rathindranath Baral
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

3.  TRPM4 regulates Akt/GSK3-β activity and enhances β-catenin signaling and cell proliferation in prostate cancer cells.

Authors:  Alfredo I Sagredo; Eduardo A Sagredo; Claudio Cappelli; Pablo Báez; Rodrigo E Andaur; Constanza Blanco; Julio C Tapia; César Echeverría; Oscar Cerda; Andrés Stutzin; Felipe Simon; Katherine Marcelain; Ricardo Armisén
Journal:  Mol Oncol       Date:  2017-12-30       Impact factor: 6.603

4.  Identification of potent and selective small molecule inhibitors of the cation channel TRPM4.

Authors:  Lijo Cherian Ozhathil; Clémence Delalande; Beatrice Bianchi; Gabor Nemeth; Sven Kappel; Urs Thomet; Daniela Ross-Kaschitza; Céline Simonin; Matthias Rubin; Jürg Gertsch; Martin Lochner; Christine Peinelt; Jean-Louis Reymond; Hugues Abriel
Journal:  Br J Pharmacol       Date:  2018-04-29       Impact factor: 8.739

5.  C10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance.

Authors:  Jie Meng; Li-Hui Wang; Chun-Lin Zou; Sheng-Ming Dai; Jian Zhang; Yi Lu
Journal:  Med Sci Monit       Date:  2017-10-30

6.  TRPM4 is highly expressed in human colorectal tumor buds and contributes to proliferation, cell cycle, and invasion of colorectal cancer cells.

Authors:  Sven Kappel; Paulina Stokłosa; Barbara Hauert; Daniela Ross-Kaschitza; Anna Borgström; Roland Baur; José A Galván; Inti Zlobec; Christine Peinelt
Journal:  Mol Oncol       Date:  2019-09-12       Impact factor: 6.603

Review 7.  TRPM4 in Cancer-A New Potential Drug Target.

Authors:  Anna Borgström; Christine Peinelt; Paulina Stokłosa
Journal:  Biomolecules       Date:  2021-02-05

8.  Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer.

Authors:  Melissa Stinnesbeck; Anna Kristiansen; Jörg Ellinger; Stefan Hauser; Lars Egevad; Yuri Tolkach; Glen Kristiansen
Journal:  APMIS       Date:  2021-02-02       Impact factor: 3.205

9.  TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer.

Authors:  María Paz Saldías; Diego Maureira; Octavio Orellana-Serradell; Ian Silva; Boris Lavanderos; Pablo Cruz; Camila Torres; Mónica Cáceres; Oscar Cerda
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 10.  Store-Operated Ca2+ Entry as a Prostate Cancer Biomarker - a Riddle with Perspectives.

Authors:  Sven Kappel; Ines Joao Marques; Eugenio Zoni; Paulina Stokłosa; Christine Peinelt; Nadia Mercader; Marianna Kruithof-de Julio; Anna Borgström
Journal:  Curr Mol Biol Rep       Date:  2017-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.